Apellis Has New Hope for Pegcetacoplan With Longer-Term Data
18-Month Results Could Vindicate Geographic Atrophy Program
Executive Summary
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.
You may also be interested in...
Finance Watch: Public Markets Open Back Up For Biopharma Offerings
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
Ex-Eylea Leader Launches Biotech Targeting Untapped Eye Market
Former Bayer executive Rafiq Hasan believes the start-up’s gene therapy candidate can open up treatment to millions of patients with dry AMD and geographic atrophy.
Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope
The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.